| Kelsey Mae Hernandez, AGACNP-BC | |
|
1600 Wallace Blvd, Amarillo, TX 79106-1799 | |
| (806) 212-2129 | |
| (806) 212-2246 |
| Full Name | Kelsey Mae Hernandez |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 1600 Wallace Blvd, Amarillo, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568064194 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2100X | Clinical Nurse Specialist - Acute Care | 1012436 (Texas) | Secondary |
| 208M00000X | Hospitalist | 1012436 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist St Anthony's Hospital | Amarillo, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bsa Physicians Group Inc | 3971748146 | 90 |
News Archive
A new technology for cancer detection that eliminates the need for drawing blood has been developed by Purdue University researchers.
The Michael J. Fox Foundation for Parkinson's Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson's disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.
A randomised crossover trial shows that zonisamide significantly improves motor symptoms and related disability in adults with myoclonus dystonia.
A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.
› Verified 5 days ago
| Entity Name | Bsa Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457696916 PECOS PAC ID: 3971748146 Enrollment ID: O20130319000147 |
News Archive
A new technology for cancer detection that eliminates the need for drawing blood has been developed by Purdue University researchers.
The Michael J. Fox Foundation for Parkinson's Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson's disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.
A randomised crossover trial shows that zonisamide significantly improves motor symptoms and related disability in adults with myoclonus dystonia.
A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelsey Mae Hernandez, AGACNP-BC Po Box 840026, Dallas, TX 75284-0026 Ph: (806) 212-6965 | Kelsey Mae Hernandez, AGACNP-BC 1600 Wallace Blvd, Amarillo, TX 79106-1799 Ph: (806) 212-2129 |
News Archive
A new technology for cancer detection that eliminates the need for drawing blood has been developed by Purdue University researchers.
The Michael J. Fox Foundation for Parkinson's Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson's disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.
A randomised crossover trial shows that zonisamide significantly improves motor symptoms and related disability in adults with myoclonus dystonia.
A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.
› Verified 5 days ago